Barinthus Biotherapeutics (BRNS) Institutional Ownership $1.04 +0.03 (+2.97%) As of 01/17/2025 03:57 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Barinthus Biotherapeutics (NASDAQ:BRNS)CurrentInstitutional OwnershipPercentage25.20%Number ofInstitutional Buyers(last 12 months)6TotalInstitutional Inflows(last 12 months)$12.27MNumber ofInstitutional Sellers(last 12 months)0 Get BRNS Insider Trade Alerts Want to know when executives and insiders are buying or selling Barinthus Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data BRNS Institutional Buying and Selling by Quarter Barinthus Biotherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/2/2024Alphabet Inc.1,513,644$2.12M0.1%N/A3.878% 7/24/2024Catalina Capital Group LLC17,819$25K0.0%N/A0.046% 7/16/2024Ipswich Investment Management Co. Inc.23,075$32K0.0%N/A0.059% 7/16/2024M&G Plc5,197,349$7.28M0.0%N/A13.316% 5/16/2024BlueCrest Capital Management Ltd542,673$1.29M0.1%N/A1.394% 5/14/2024DC Funds LP642,204$1.53M14.8%N/A1.650% (Data available from 1/1/2016 forward) BRNS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of BRNS shares? During the previous two years, the following institutional investors and hedge funds held shares of Barinthus Biotherapeutics shares: M&G Plc ($7.28M), Alphabet Inc. ($2.12M), DC Funds LP ($1.53M), BlueCrest Capital Management Ltd ($1.29M), and Ipswich Investment Management Co. Inc. ($32K), Catalina Capital Group LLC ($25K).Learn more on BRNS's institutional investors. What percentage of Barinthus Biotherapeutics stock is owned by institutional investors? 25.20% of Barinthus Biotherapeutics stock is owned by institutional investors. Learn more on BRNS's institutional investor holdings. Which institutional investors have been buying Barinthus Biotherapeutics stock? The following institutional investors have purchased Barinthus Biotherapeutics stock in the last 24 months: M&G Plc ($5.20M), Alphabet Inc. ($1.51M), DC Funds LP ($642.20K), BlueCrest Capital Management Ltd ($542.67K), Ipswich Investment Management Co. Inc. ($23.08K), and Catalina Capital Group LLC ($17.82K). How much institutional buying is happening at Barinthus Biotherapeutics? Institutional investors have bought a total of 7,936,764 shares in the last 24 months. This purchase volume represents approximately $12.27M in transactions. Related Companies PBYI Institutional Ownership IPHA Institutional Ownership BMEA Institutional Ownership CDTX Institutional Ownership STRO Institutional Ownership FATE Institutional Ownership TCRX Institutional Ownership INMB Institutional Ownership RENB Institutional Ownership KYTX Institutional Ownership This page (NASDAQ:BRNS) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
